PDX Breast Cancer Model WHIM10

Technical Information
Published in Cell Reports, WHIM10 is a highly characterized, triple negative (HER2-, ER-, PR-) PDX model of breast cancer. Derived from a skin metastasis, this line possesses a Y220C mutation in p53.

Technical Data

Whole Genome Sequenced
No
RNA Sequence
No

Tumor Information

Availability
Available
Tumor Site
Metastasis: Skin
Patient Number
10

Patient Demographics

Age at Diagnosis
N/A
Family History
N/A

PAM50 Subtype

PAM50 Originating Tumor
N/A
PAM50 Early Passage
Basal
PAM50 Late Passage
Basal

Genotype/Mutations

ER Status
Negative
PR Status
Negative
HER2 Status
Negative
p53 Genotype
Y220C
PIK3CA Genotype
WT
ESR1 Genotype
WT
Phosphoprotein Highest Rank
N/A

PAM50 Subtype Expression

PAM50 Microarray Validation
PDX Breast Cancer Model WHIM10 - PAM50 Microarray Validation
Validation of PAM50 microarray. Coclustering of 250 human breast samples representing all the PAM50 intrinsic subtypes and 22 HIM models using the 50 PAM50 genes. Gene expression data of all samples has been obtained using 244K Agilent microarrays.
Claudin Low Signature
PDX Breast Cancer Model WHIM10 - Claudin Low Signature
Microarray of 807 genes that make up the Claudin-low signature. On the right, the expression of each gene (up- or downregulated) of the Claudin-low signature is shown. The two Claudin-low samples (WHIM12 and WHIM17) are identified below the array tree.
Protocols & Documents
Reviews

Write Your Own Review

You're reviewing: PDX Breast Cancer Model WHIM10

How do you rate this product? *

 
1 1 star
2 2 star
3 3 star
4 4 star
5 5 star
Value
Quality
Price
Back to top